Gyermekkori daganatok: vizsgálatok itt: Kína
611 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- No phaseTaking peopleRegistry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
- Where
- Shanghai
- Életkor
- 14 év and over
- People
- 500
- Run by
- Ruijin Hospital
See details and how to joinNCT06534463 - 2. fázisTaking peopleTrilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
- Where
- Beijing
- Életkor
- 14 év to 70 év
- People
- 50
- Run by
- Peking University People's Hospital
See details and how to joinNCT06714383 - No phaseTaking peopleTaxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
- Where
- Beijing
- People
- 285
- Run by
- Shu Wang
See details and how to joinNCT06711055 - No phaseTaking peopleAdjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
- Where
- Beijing
- People
- 8077
- Run by
- Shu Wang
See details and how to joinNCT06711068 - 4. fázisCsak meghívásosExploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia
- Where
- Wuhan
- Életkor
- 1 nap to 7 év
- People
- 180
- Run by
- Yilin Zhao
See details and how to joinNCT06711679 - No phaseNot yet taking people in KínaPrognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy
- Where
- Shanghai
- People
- 100
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT06608225 - No phaseTaking peopleDe-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
- Where
- Beijing
- People
- 519
- Run by
- Shu Wang
See details and how to joinNCT06700369 - No phaseTaking peopleDifferent Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
- Where
- Beijing
- People
- 1166
- Run by
- Shu Wang
See details and how to joinNCT06700382 - 2. fázisTaking peopleA Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
- Where
- Shanghai
- Életkor
- 14 év to 40 év
- People
- 22
- Run by
- Fudan University
See details and how to joinNCT06699472 - No phaseTaking peopleDe-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
- Where
- Beijing
- People
- 380
- Run by
- Peking University People's Hospital
See details and how to joinNCT06692725 - No phaseTaking peopleAdjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
- Where
- Beijing
- People
- 2806
- Run by
- Shu Wang
See details and how to joinNCT06693024 - No phaseTaking peopleAdjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
- Where
- Beijing
- People
- 2092
- Run by
- Shu Wang
See details and how to joinNCT06693037 - Korai 1. fázisTaking peopleAllogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Where
- Suzhou
- Életkor
- 14 év and over
- People
- 18
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT06696833 - No phaseCsak meghívásosPerioperative Treatment Outcomes of Early NSCLC
- Where
- Shanghai
- People
- 500
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT06610240 - 1/2. fázisTaking peopleSequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
- Where
- Beijing
- Életkor
- 6 év to 90 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06420063 - 1/2. fázisTaking peopleSequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
- Where
- Beijing
- Életkor
- 2 év to 90 év
- People
- 60
- Run by
- Essen Biotech
See details and how to joinNCT06420076 - 1/2. fázisTaking peopleTIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
- Where
- Beijing
- Életkor
- 16 év to 90 év
- People
- 75
- Run by
- Essen Biotech
See details and how to joinNCT06532799 - 1/2. fázisTaking peopleTIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
- Where
- Beijing
- Életkor
- 16 év to 90 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06532812 - 1/2. fázisTaking peopleBiological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
- Where
- Beijing
- Életkor
- 16 év to 90 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06530303 - 2. fázisTaking peopleCombination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
- Where
- Tianjin
- Életkor
- 16 év to 70 év
- People
- 20
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06608732 - 1/2. fázisTaking peopleTIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
- Where
- Beijing
- Életkor
- 16 év to 90 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06640582 - 3. fázisNot yet taking people in KínaBuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
- Where
- Suzhou
- Életkor
- 2 év to 55 év
- People
- 430
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT06673459 - 1. fázisNot yet taking people in KínaCAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
- Where
- Zhengzhou
- Életkor
- 14 év to 75 év
- People
- 30
- Run by
- Mingzhi Zhang
See details and how to joinNCT06647329 - 1/2. fázisTaking peopleTIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
- Where
- Beijing
- Életkor
- 16 év to 90 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06538012 - Korai 1. fázisTaking peopleTargeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
- Where
- Hangzhou
- People
- 30
- Run by
- Zhejiang University
See details and how to joinNCT06633341